Register for our free email digests:
Athersys, Inc.
http://www.athersys.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Athersys, Inc.
Scrip Asks…What Does 2021 Hold For Biopharma? Part 5: Business Environment And Strategy
A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.
Scrip Asks…What Does 2021 Hold For Biopharma? Part 4: Technology And Disease
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Scrip Asks…What Does 2021 Hold For Biopharma? Part 2: COVID-19 Shock Waves And Silver Linings
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.
Coronavirus Update: Will Moderna Really Demand Premium Price For COVID Vaccine?
There are reports that the US biotech is considering pricing its as-yet-unapproved mRNA-1273 at $25-30 a dose, a price which would double as both a prime and boost dose would be administered.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- BTHC VI Inc.